Prediction of broad spectrum resistance of tumors towards anticancer drugs

	Prediction of broad spectrum resistance of tumors towards anticancer drugs
	Efferth, Thomas ; Konkimalla, V. Badireenath ; Wang, Yi-Fen ; Sauerbrey, Axel ; Meinhardt, Silke ; Zintl, Felix ; Mattern, Juegen ; Volm, Manfred
通讯作者	Efferth, T (reprint author), German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany. t.efferth@dkfz.de
	2008
发表期刊	CLINICAL CANCER RESEARCH
ISSN	1078-0432
卷号	14 期号:8 页码:2405-2412
摘要	Purpose: Drug resistance is a major obstacle in cancer chemotherapy. Although the statistical probability of therapeutic success is known for larger patient groups from clinical therapy trials, it is difficult to predict the individual response of tumors. The concept of individualized therapy aims to determine in vitro the drug response of tumors beforehand to choose effective treatment options for each individual patient. Experimental Design: We analyzed the cross-resistance profiles of different tumor types (cancers of lung, breast, and colon, and leukemia) towards drugs from different classes (anthracyclines, antibiotics, Vinca alkaloids, epipodophyllotoxins, antimetabolites, and alkylating agents) by nucleotide incorporation and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Hierarchical cluster analysis and COMPARE analyses were applied. Results: Tumors exert broad resistance profiles, e.g., tumors resistant to one drug tend to also be resistant to other drugs, whereas sensitive tumors reveal sensitivity towards many drugs. Interestingly, the broad spectrum resistance phenotype could reliably be predicted by doxorubicin alone. Expression of the ATP-binding cassette transporter P-glycoprotein (ABCB1, MDR1) and the proliferative activity of tumors were identified as underlying mechanisms of broad spectrum resistance. To find novel compounds with activity against drug-resistant tumors, a database with 2,420 natural products was screened for compounds acting independent of P-glycoprotein and the proliferative state of tumor cells. Conclusions: umors exert cross-resistance profiles much broader than the classical multidrug resistance phenotype. Broad spectrum resistance can be predicted by doxorubicin due to the multifactorial mode of action of this drug. Novel cytotoxic compunds from natural resources might be valuable tools for strategies to bypass broad spectrum resistance.
关键词	Traditional Chinese Medicine Cassette Transporter Genes Short-term Test Multidrug-resistance Cell-lines Cancer-chemotherapy Tetrazolium Assay Sensitivity Leukemia Cytotoxicity
学科领域	Oncology
收录类别	sci
语种	English
文献类型	期刊论文
条目标识符	http://ir.kib.ac.cn/handle/151853/15388
专题	植物化学与西部植物资源持续利用国家重点实验室
推荐引用方式 GB/T 7714	Efferth, Thomas,Konkimalla, V. Badireenath,Wang, Yi-Fen,et al. Prediction of broad spectrum resistance of tumors towards anticancer drugs[J]. CLINICAL CANCER RESEARCH,2008,14(8):2405-2412.
APA	Efferth, Thomas.,Konkimalla, V. Badireenath.,Wang, Yi-Fen.,Sauerbrey, Axel.,Meinhardt, Silke.,...&Volm, Manfred.(2008).Prediction of broad spectrum resistance of tumors towards anticancer drugs.CLINICAL CANCER RESEARCH,14(8),2405-2412.
MLA	Efferth, Thomas,et al."Prediction of broad spectrum resistance of tumors towards anticancer drugs".CLINICAL CANCER RESEARCH 14.8(2008):2405-2412.

条目包含的文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
2012101512.pdf（210KB）			开放获取	--	浏览请求全文